PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology)

N/A

Report date: 2024/12/20 10:11:47

Base Information

Drug NamePD-1 knockout engineered T cells (Anhui Kedgene Biotechnology)
Drug Alias NamePD-1敲出工程化T细胞（安徽柯顿）PD-1敲除工程化T细胞（安徽柯顿）PD-1基因定制活化T细胞注射液
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAnhui Korton Biological Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnhui Korton Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsEsophageal NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A